Epigenetic Predictors Of Outcome In Malignant Glioma
Funder
National Health and Medical Research Council
Funding Amount
$697,720.00
Summary
Human high grade gliomas (HGG) present as heterogeneous disease, primarily defined by the histologic appearance of the tumor cells.Glioblastoma multiforme (GBM) is the most common illness and continues to have a very poor prognosis, despite the use of multimodality therapy including surgery, radiation therapy and chemotherapy. We will use our existing biobank of specimens, clinical information and molecular investigation to identify factors that determine outcomes.
The Landscape Of Cancer Genes And Associations With Prognosis In Breast Cancer Diagnosed In Premenopausal Women
Funder
National Health and Medical Research Council
Funding Amount
$700,512.00
Summary
Using state of the art technology, the purpose of this project is understand the implications of known cancer mutations in breast cancer diagnosed in premenopausal ER-positive breast cancer. Mutations are abnormalities in the DNA of genes that can provide a signal for uncontrolled growth, a hallmark of cancer. The unique aspect of this project is use of tissue samples from patients who were diagnosed with breast cancer at a young age. This information will help us develop new treatments.
Prediction Of Adverse Outcomes Following A Fragility Fracture
Funder
National Health and Medical Research Council
Funding Amount
$148,426.00
Summary
Individuals with an existing fracture are at increased risk of adverse outcomes such as re-fracture and premature mortality, but it is not clear why. We propose to evaluate risk factors, and prognostic models, for predicting the risk of adverse outcomes. We also propose to develop a quantitative risk-benefit framework for evaluating the clinical utility of such prognostic models and help ensure that therapies appropriately address real-life experience of osteoporotic patients.
Characterising The Mutations, Signatures, Potential New Therapeutic Targets And Biomarkers In Malignant Mesothelioma Using Whole Genome Analysis.
Funder
National Health and Medical Research Council
Funding Amount
$1,219,288.00
Summary
Malignant mesothelioma is an aggressive tumour that occurs principally in the pleura as a consequence of inhaling asbestos fibres. Currently there is no cure for malignant mesothelioma. Thus new therapeutic approaches are desperately needed. Such new approaches will require a detailed understanding of the genetic lesions of malignant mesothelioma. Therefore we will perform whole genome sequencing of a large cohort of malignant mesothelioma patients to identify mesothelioma-related alterations.
Early Diagnosis And Prognosis Of Severe Dengue In Vietnamese Children
Funder
National Health and Medical Research Council
Funding Amount
$689,323.00
Summary
Dengue is a mosquito-borne viral infection. Tropical Australia has experienced multiple outbreaks of dengue in the last decade. This project, conducted in Ho Chi Minh City, Viet Nam, will define the accuracy of a rapid diagnostic test for the early diagnosis of severe dengue. In doing so, we will also derive an algorithm using simple laboratory and clinical findings that can help identify those patients at greatest risk of severe complications, with benefits for both patients and hospitals.
Multiple Sclerosis: Does Treatment Reduce Long-term Disability Progression?
Funder
National Health and Medical Research Council
Funding Amount
$349,103.00
Summary
Multiple Sclerosis is an illness affecting more than 20,000 Australians, and causes significant disability and social disruption in most sufferers. It is an illness which progresses over decades, and this makes it difficult to accurately determine the best treatment strategies. We propose to use a registry that has followed more than 16,000 people with MS globally to examine which treatment strategies have provided the highest benefit/risk ratio in these patients, given the great variability of ....Multiple Sclerosis is an illness affecting more than 20,000 Australians, and causes significant disability and social disruption in most sufferers. It is an illness which progresses over decades, and this makes it difficult to accurately determine the best treatment strategies. We propose to use a registry that has followed more than 16,000 people with MS globally to examine which treatment strategies have provided the highest benefit/risk ratio in these patients, given the great variability of disease severity seen.Read moreRead less
Development Of Serum Models That Can Predict Clinical Outcomes In Chronic Liver Disease
Funder
National Health and Medical Research Council
Funding Amount
$380,694.00
Summary
The overall objective of this project is to develop blood tests that can accurately predict liver related death, liver cancer and liver decompensation respectively for patients with chronic liver disease. Blood tests will also be developed to predict cardiovascular disease in patients with non-alcoholic fatty liver disease. Furthermore, we will evaluate the use of repeated blood tests to assess if this can more accurately predict death and complications compared to a single time point.
Is The Eye A Window To The Brain In Sanfilippo Syndrome?
Funder
National Health and Medical Research Council
Funding Amount
$852,967.00
Summary
Study of the retina and optic nerve permits evaluation of central nervous system – these structures contain both neurons and glia and are outgrowths of the developing brain. Therefore, eye examination may allow us to study the brain and monitor brain disease and the effect of therapy. This project will determine whether brain disease in a childhood-onset disorder (Sanfilippo syndrome) and treatment of it, can be monitored in this way.
Temporal Trends In The Incidence, Site And Survival Of Metastatic Breast Cancer In Australia
Funder
National Health and Medical Research Council
Funding Amount
$190,494.00
Summary
There have been major advances in breast cancer treatment over the last decade. This project will use information collected from the NSW cancer registry and hospitals to report on changes in the type and risk of breast cancer spread and survival for women with a new diagnosis of breast cancer before and after new treatments introduced since 2005. This information is essential for doctors to provide women with up-to-date information; and for planning appropriate health services and research.
From Transcriptome Metanalysis To Targeted Therapies In Triple Negative Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$483,363.00
Summary
We identified a gene expression signature, a genetic fingerprint, that identifies patients who are affected by very aggressive forms of breast cancer. In this project, we will develop a clinically relevant test that can be used to guide treatment planning against aggressive types of breast cancer to improve survival rates. In addition we will validate new and novel targets for future drug development against these aggressive subtypes.